Grace Therapeutics Statistics
Total Valuation
GRCE has a market cap or net worth of $40.52 million. The enterprise value is $18.38 million.
Important Dates
The last earnings date was Monday, June 23, 2025, before market open.
Earnings Date | Jun 23, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
GRCE has 13.83 million shares outstanding. The number of shares has increased by 27.10% in one year.
Current Share Class | 13.72M |
Shares Outstanding | 13.83M |
Shares Change (YoY) | +27.10% |
Shares Change (QoQ) | +21.04% |
Owned by Insiders (%) | 18.50% |
Owned by Institutions (%) | 11.06% |
Float | 7.60M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.60 |
P/TBV Ratio | 2.34 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.77
Current Ratio | 11.77 |
Quick Ratio | 11.53 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -14.91% and return on invested capital (ROIC) is -16.24%.
Return on Equity (ROE) | -14.91% |
Return on Assets (ROA) | -14.35% |
Return on Invested Capital (ROIC) | -16.24% |
Return on Capital Employed (ROCE) | -23.81% |
Revenue Per Employee | n/a |
Profits Per Employee | -$299,000 |
Employee Count | 32 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | -3.20M |
Effective Tax Rate | n/a |
Dividends & Yields
GRCE does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -27.10% |
Shareholder Yield | -27.10% |
Earnings Yield | -23.61% |
FCF Yield | -36.78% |
Analyst Forecast
The average price target for GRCE is $12.00, which is 309.56% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $12.00 |
Price Target Difference | 309.56% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | -5.20% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on July 10, 2023. It was a reverse split with a ratio of 0.1666667:1.
Last Split Date | Jul 10, 2023 |
Split Type | Reverse |
Split Ratio | 0.1666667:1 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |